When was Vor Biopharma founded?

Vor Biopharma was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is Vor Biopharma located?

Vor Biopharma is headquartered in Cambridge, United States.

How many employees does Vor Biopharma have?

As of Jul 31, 2026, the latest employee count at Vor Biopharma is 129.

Is Vor Biopharma a funded company?

Vor Biopharma is a funded company, having raised a total of $152M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Feb 14, 2019.

When was the latest funding round of Vor Biopharma?

Vor Biopharma's latest funding was a $***** Post IPO round on Dec 15, 2025, with participation from 6 investors.

Where does Vor Biopharma rank among its competitors?

Vor Biopharma ranks 2nd amongst 96 active competitors, of which 21 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was BioStem Technologies, which secured $2.5M in May, 2026.

Who are the top competitors of Vor Biopharma?

Vor Biopharma's top competitors include argenx, Horizon Therapeutics and Radius Health. Among them, BioStem Technologies secured the most recent funding round in May, 2026.

Vor Biopharma - 2026 Company Profile, Team, Funding, Competitors & Financials

Vor Biopharma is a public company based in Cambridge (United States), founded in 2019 by Siddhartha Mukherjee. It operates as a Developer of therapeutics to treat acute myeloid leukemia. Vor Biopharma has raised $152M in funding. The company has 96 active competitors, including 21 funded and 26 that have exited. Its top competitors include companies like argenx, Horizon Therapeutics and Radius Health.

Company Details

Developer of therapeutics to treat acute myeloid leukemia. The company has developed cancer therapeutics using engineered hematopoietic stem cells (eHSC). The company's lead candidate includes VOR33 which targets CD33 protein in cancer patients to treat acute myeloid leukemia (AML).

Website: www.vorbio.com
Email ID: *****@vorbio.com
Phone Number: +1 **********

Key Metrics

Founded Year

2019

Location

Cambridge, United States

Stage

Public

Total Funding

$152M in 4 rounds

Latest Funding Round

Post IPO, Dec 15, 2025, $*****

Investors

HTIF & 11 more

Ranked

2^nd among 96 active competitors

Employee Count

129 as on Jul 31, 2026

Similar Companies

argenx & 116 more

Exit Details

Public

View Vor Biopharma's full profile

Vor Biopharma is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Vor Biopharma Inc. CIN: 1817229 , United States, Active	Dec 29, 2015	-	133 (As on Mar 31, 2023)	-
BIOPHARMA INC. CIN: 2336740 , United States, Active	May 17, 1993	-	-	-

Vor Biopharma got listed on Feb 05, 2021.

Click here to take a look at Vor Biopharma's IPO in detail

Vor Biopharma has raised a total funding of $152M over 4 rounds. Its first funding round was on Feb 14, 2019. Its latest funding round was a Post IPO round on Dec 15, 2025 for $*****. 6 investors participated in its latest round. Vor Biopharma has 12 institutional investors.

Here is the list of recent funding rounds of Vor Biopharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 15, 2025	5068009	Post IPO	2397200	8838179	4857425	3106804
Jun 25, 2025	5522393	Post IPO	4245349	2895639	1474388	RA Capital Management & 4 more
Jul 07, 2020	5039303	Series B	8729612	4999992	6773015	4858201

Access funding benchmarks and valuations. Sign up today!

View details of Vor Biopharma's funding rounds and investors

The founders of Vor Biopharma is Siddhartha Mukherjee.

Here are the details of Vor Biopharma's key team members:

Siddhartha Mukherjee: Founder of Vor Biopharma and founder of 2 other companies, CuraPatient and Immuneel. They serve on the board of 1 company.
Contact Info: 2 email addresses

View details of Vor Biopharma's Founder profiles and Board Members

Vor Biopharma's employee count trend

Vor Biopharma has 129 employees as of Jul 26. Here is Vor Biopharma's employee count trend over the years:

Uncover Vor Biopharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vor Biopharma include argenx, Horizon Therapeutics and Radius Health. Here is the list of Top 10 competitors of Vor Biopharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 20 others	75/100
2nd	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	HTIF, Venrock & 10 others	67/100
3rd	Horizon Therapeutics 2008, Dublin (Ireland), Acquired	Developer of drugs for treating rare and autoimmune diseases	$61.8M	Atlas Venture, Quaker Partners Management ... & 4 others	64/100
4th	Radius Health 2003, Boston (United States), Acquired	Biopharmaceutical company focused on bone health and related therapeutic areas	$213M	MPM BioImpact, Wellcome & 14 others	63/100
5th	Quince Therapeutics 2012, San Francisco (United States), Public	Developer of therapeutics for orthopedic diseases	$108M	Pfizer Venture Investments, Balyasny Asset Management ... & 26 others	60/100
6th	Angitia 2018, Woodland Hills (United States), Series D	Developer of drugs for muscle, bone, and joint diseases	$406M	Morningside, Bain Capital Life Sciences & 28 others	58/100
7th	Valitor 2010, Berkeley (United States), Series B	Developer of therapeutic proteins for multiple disease conditions	$38.2M	Morningside, The House Fund & 9 others	55/100
8th	Ingeneron 2005, Houston (United States), Series D	Developer of cell-separation technology for regenerative medicine	$51.4M	Sanford Health, German Accelerator	54/100
9th	Vuja De Sciences 2017, Hoboken (United States), Seed	Developer of therapies for preventing metastasis and recurrence of cancers	$3.94M	-	51/100
10th	BioStem Technologies 2006, Pompano Beach (United States), Public	Provider of placental-based amniotic tissue products	-	-	51/100